BCDA
BioCardia, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.06
−2.75%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | 58.0K | 477.0K | 1.4M |
| Cost of Revenue | 540.0K | 505.0K | 4.4M | 7.7M | 8.8M |
| Gross Profit | (540.0K) | (505.0K) | (4.3M) | (7.2M) | (7.5M) |
| Operating Expenses | |||||
| R&D Expense | 4.2M | 5.0M | 4.4M | 7.7M | 8.8M |
| SG&A Expense | 2.9M | 3.3M | — | — | — |
| General & Admin Expense | 730.0K | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (248.0K) | (505.0K) | (715.0K) | (3.3M) | (4.4M) |
| Total Operating Expenses | 6.8M | 7.8M | 3.7M | 4.4M | 4.4M |
| Cost and Expenses | 7.4M | 8.3M | 8.1M | 12.1M | 13.3M |
| Operating Income (EBIT) | (7.4M) | (8.3M) | (8.0M) | (11.6M) | (11.9M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | 6.0K |
| Net Interest Income | — | — | — | — | (6.0K) |
| Other Non-Op Income/Expense | 51.0K | 50.0K | 55.0K | 73.0K | (6.0K) |
| Non-Operating Income (excl Interest) | (51.0K) | (50.0K) | (55.0K) | (73.0K) | — |
| EBT (Pre-Tax Income) | (7.3M) | (8.2M) | (7.9M) | (11.6M) | (11.9M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (7.3M) | (8.2M) | (7.9M) | (11.6M) | (11.9M) |
| Earnings from Cont. Ops | (7.3M) | (8.2M) | (7.9M) | (11.6M) | (11.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (7.3M) | (8.2M) | (7.9M) | (11.6M) | (11.9M) |
| Per Share | |||||
| Basic EPS | ($0.76) | ($1.23) | ($2.90) | ($8.19) | ($10.05) |
| Diluted EPS | ($0.76) | ($1.23) | ($2.90) | ($8.19) | ($10.05) |
| Revenue Per Share | $0.00 | $0.00 | $0.02 | $0.34 | $1.14 |
| Shares | |||||
| Basic Shares Outstanding | 12.1M | 6.7M | 2.7M | 1.4M | 1.2M |
| Diluted Shares Outstanding | 12.1M | 6.7M | 2.7M | 1.4M | 1.2M |
| Profitability Metrics | |||||
| EBITDA | (6.8M) | (7.7M) | (7.9M) | (11.5M) | (11.8M) |
| D&A | 540.0K | 505.0K | 67.0K | 84.0K | 82.0K |
| EBIT | (7.3M) | (8.2M) | (7.9M) | (11.6M) | (11.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026